A national consensus management pathway for paediatric inflammatory multisystem syndrome temporally associated with COVID-19 (PIMS-TS): results of a national Delphi process.
Journal
The Lancet. Child & adolescent health
ISSN: 2352-4650
Titre abrégé: Lancet Child Adolesc Health
Pays: England
ID NLM: 101712925
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
05
08
2020
revised:
20
08
2020
accepted:
21
08
2020
pubmed:
22
9
2020
medline:
2
2
2021
entrez:
21
9
2020
Statut:
ppublish
Résumé
Paediatric inflammatory multisystem syndrome temporally associated with COVID-19 (PIMS-TS) is a novel condition that was first reported in April, 2020. We aimed to develop a national consensus management pathway for the UK to provide guidance for clinicians caring for children with PIMS-TS. A three-phase online Delphi process and virtual consensus meeting sought consensus over the investigation, management, and research priorities from multidisciplinary clinicians caring for children with PIMS-TS. We used 140 consensus statements to derive a consensus management pathway that describes the initial investigation of children with suspected PIMS-TS, including blood markers to help determine the severity of disease, an echocardiogram, and a viral and septic screen to exclude other infectious causes of illness. The importance of a multidisciplinary team in decision making for children with PIMS-TS is highlighted throughout the guidance, along with the recommended treatment options, including supportive care, intravenous immunoglobulin, methylprednisolone, and biological therapies. These include IL-1 antagonists (eg, anakinra), IL-6 receptor blockers (eg, tocilizumab), and anti-TNF agents (eg, infliximab) for children with Kawasaki disease-like phenotype and non-specific presentations. Use of a rapid online Delphi process has made it possible to generate a national consensus pathway in a timely and cost-efficient manner in the middle of a global pandemic. The consensus statements represent the views of UK clinicians and are applicable to children in the UK suspected of having PIMS-TS. Future evidence will inform updates to this guidance, which in the interim provides a solid framework to support clinicians caring for children with PIMS-TS. This process has directly informed new PIMS-TS specific treatment groups as part of the adaptive UK RECOVERY trial protocol, which is the first formal randomised controlled trial of therapies for PIMS-TS globally.
Identifiants
pubmed: 32956615
pii: S2352-4642(20)30304-7
doi: 10.1016/S2352-4642(20)30304-7
pmc: PMC7500943
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
133-141Subventions
Organisme : Department of Health
ID : CS-2015-15-016
Pays : United Kingdom
Investigateurs
Rachel Agbeko
(R)
Octavio Aragon
(O)
Jim Baird
(J)
Alasdair Bamford
(A)
Michael Bereford
(M)
Tara Bharucha
(T)
Paul Brogan
(P)
Karina Butler
(K)
Enitan Carroll
(E)
Katrina Cathie
(K)
Ashish Chikermane
(A)
Sharon Christie
(S)
Matthew Clark
(M)
Antigoni Deri
(A)
Conor Doherty
(C)
Simon Drysdale
(S)
Phouc Duong
(P)
Saravanan Durairaj
(S)
Marieke Emonts
(M)
Jennifer Evans
(J)
James Fraser
(J)
Scott Hackett
(S)
Rosie Hague
(R)
Paul Heath
(P)
Jethro Herberg
(J)
Marina Ilina
(M)
Nicola Jay
(N)
Dominic Kelly
(D)
Caroline Kerrison
(C)
Jeannette Kraft
(J)
Alice Leahy
(A)
Mike Linney
(M)
Hermione Lyall
(H)
Liza McCann
(L)
Paddy McMaster
(P)
Owen Miller
(O)
Sean O'Riordan
(S)
Stephen Owens
(S)
Clare Pain
(C)
Sanjay Patel
(S)
Nazima Pathan
(N)
James Pauling
(J)
David Porter
(D)
Andrew Prendergast
(A)
Kumar Ravi
(K)
Andrew Riorden
(A)
Marion Roderick
(M)
Barnaby R Scholefield
(BR)
Malcolm G Semple
(MG)
Ethan Sen
(E)
Fiona Shackley
(F)
Ian Sinha
(I)
Shane Tibby
(S)
Stefania Verganano
(S)
Steven B Welch
(SB)
Nicholas Wilkinson
(N)
Mark Wood
(M)
Iain Yardley
(I)
Commentaires et corrections
Type : ErratumIn
Informations de copyright
Copyright © 2021 Elsevier Ltd. All rights reserved.
Références
Arch Dis Child. 2017 Dec;102(12):1143-1151
pubmed: 28784616
Lancet Child Adolesc Health. 2020 Sep;4(9):669-677
pubmed: 32653054
PLoS Med. 2011 Jan 25;8(1):e1000393
pubmed: 21283604
BMJ. 2020 Jun 3;369:m2094
pubmed: 32493739
Lancet. 2020 May 23;395(10237):1607-1608
pubmed: 32386565
Pediatr Blood Cancer. 2007 Feb;48(2):124-31
pubmed: 16937360
BMJ. 2020 Aug 27;370:m3249
pubmed: 32960186
Circulation. 2017 Apr 25;135(17):e927-e999
pubmed: 28356445
BJOG. 2018 Nov;125(12):1612-1618
pubmed: 29770557
Lancet. 2020 Jun 6;395(10239):1771-1778
pubmed: 32410760
Trials. 2017 Jun 20;18(Suppl 3):280
pubmed: 28681707
Arch Dis Child Fetal Neonatal Ed. 2019 Jan;104(1):F76-F82
pubmed: 29540463
MMWR Morb Mortal Wkly Rep. 2020 Aug 14;69(32):1074-1080
pubmed: 32790663
JAMA. 2020 Jul 21;324(3):259-269
pubmed: 32511692
Arthritis Rheumatol. 2020 Nov;72(11):1791-1805
pubmed: 32705809
Circulation. 2020 Aug 4;142(5):429-436
pubmed: 32418446
Hosp Pediatr. 2020 Jun;10(6):537-540
pubmed: 32265235